| Customization: | Available |
|---|---|
| Package: | 100ml/Bottle |
| Composition: | 20% Mannitol |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product | Dose | Package |
| 20% Mannitol Injection | 100ml | 100ml/Bottle |
20% Mannitol Injection is a sterile solution of mannitol, a sugar alcohol, administered intravenously for its osmotic diuretic properties. It is primarily used in the treatment of cerebral edema, a condition characterized by the accumulation of excess fluid in the brain, often resulting from traumatic brain injury, stroke, or brain surgery. Mannitol acts by drawing water out of brain cells into the bloodstream, thereby reducing intracranial pressure and improving cerebral perfusion.
20% Mannitol Injection is administered intravenously under medical supervision. The dosage and rate of administration depend on the severity of cerebral edema and the patient's clinical status. It is typically administered as a slow infusion over a period of 30 to 60 minutes to minimize the risk of adverse effects such as rapid changes in serum osmolality.
Prior to administration, the solution should be inspected visually for particulate matter and discoloration. Any unused portion of the solution should be discarded according to established protocols.
Precautions:
While 20% Mannitol Injection is generally considered safe and well-tolerated, it should be used with caution in patients with preexisting renal impairment, heart failure, or electrolyte imbalances. Close monitoring of electrolyte levels, renal function, and fluid status is recommended during mannitol therapy.
In patients with compromised blood-brain barrier integrity or severe dehydration, mannitol infusion may exacerbate cerebral edema or lead to hyperosmolar complications. Careful patient selection and monitoring are essential to minimize the risk of adverse effects.
){kind=link}